Exploring ebselen Derivatives for Parkinson's Disease Therapy

This qualification project has explored Ebselen as a potential disease-modifying treatment (DMT) for Parkinson’s disease (PD), with a focus on patients showing mitochondrial dysfunction, a key driver of disease progression in a significant PD subgroup. Current PD treatments relieve symptoms but do not stop the disease. Ebselen, a synthetic compound, has shown promise in restoring mitochondrial function and protecting neurons. The aim of this project was to assess Ebselen and its known derivatives to identify candidates with therapeutic potential and a clear path to further development. We established contact with AFM Téléthon, a French consortium behind a key patent on Ebselen in PD. However, delays in receiving samples led us to independently purchase Ebselen derivatives from commercial suppliers. These were tested in disease-relevant assays, and their intellectual property (IP) status was reviewed by patent attorneys. The results identified Compound 5 as a promising, unpatented candidate with biological activity and freedom to operate. This enables further development without infringing existing patents. The project was lead by Vestlandets innovasjonsselskap (VIS) and the experimental tests were carried out by the KG Jebsen Centre for Parkinson’s Disease at the University of Bergen The team brings deep expertise in mitochondrial biology, PD, and commercialisation strategy. Although no public dissemination has occurred due to confidentiality, key findings have been shared with stakeholders who have confirmed strategic interest in the area. The project has laid a solid foundation for further development and funding applications, and contributes to the long-term goal of offering more targeted and effective treatments for PD patients.

This project has built a platform for targeted, mechanism-based therapy in PD, laying the groundwork for biomarker-guided clinical trials. On a long term the findings can be expected to benefit: • The research field, by supporting translational PD models. • Patients, through future personalised treatment strategies. • Society, by reducing the long-term cost burden of PD care. • Industry, via partnership or licensing opportunities.